Here’s Why the Approval of Lupkynis Has Biotech Investors Buzzing

The US Food and Drug Administration (FDA) has approved the first oral drug for lupus nephritis called Lupkynis (voclosporin). This drug — developed by Vancouver, Canada-based Aurinia Pharmaceuticals — is used to treat a kidney disease that is caused by lupus which can lead to kidney failure, heart complications and even death.